Terumo Europe announces today that it has received MDR approval for an expanded indication of its Ultimaster Nagomi™ and Ultimaster™ Tansei™ sirolimus eluting coronary stent systems.​

​

​Terumo Europe delighted to share that a positive guidance has been published by NICE mentioning that Holmium-166 Selective Internal Radiation Therapy (SIRT) using QuiremSpheres^TM microspheres is recommended as an option for treating HCC patients with child-Pugh grade A liver impairment, when conventional transarterial therapies are inappropriate. ​​

​

Terumo Europe is delighted to share that a positive guidance has been published by NICE stating that Selective Internal Radiation Therapy (SIRT) is now recommended to be used for the treatment of neuroendocrine tumors with liver metastasis (NELM).

This is a key milestone as it expands the existing treatment options (surgery, percutaneous ablation, systemic therapies, peptide receptor radionuclide therapy (PRRT) & other intra-arterial therapies) for the treatment of patients with NELM.  ​

Terumo Europe N.V. is pleased to announce the launch of BioPearl^TM microspheres, the first resorbable drug-eluting microspheres. We are continuing our commitment to advancing TACE by adding our latest innovation and to expanding your TACE therapeutic options. BioPearl^TM microspheres are designed to combine the confidence from the drug-eluting microspheres technology and the benefits of a resorbable agent.​​​

​Terumo Europe N.V. announces the launch of the BIOPEARL-ONE study, a new multi-center post market clinical trial: BioPearl^TM microspheres are loaded with doxorubicin to treat patients with unresectable hepatocellular carcinoma (HCC). A prospective, single arm, multi-centre post-market follow-up study is intended to assess the safety and efficacy of BioPearl^TM microspheres loaded with doxorubicin in the treatment of patients with unresectable HCC. ​